Amivantamab Intravenous

DRUG2 trials

Sponsors

Janssen Research & Development, LLC, University Hospital, Essen

Conditions

Advanced or Metastatic Non-small Cell Lung CancerLung Cancer (NSCLC)

Phase 2

Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)

RecruitingNCT06784791

University Hospital, EssenLung Cancer (NSCLC)

Start: 2024-11-06End: 2027-12-31Target: 20Updated: 2025-08-29

Phase 3

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Active, not recruitingNCT05388669

Janssen Research & Development, LLCAdvanced or Metastatic Non-small Cell Lung Cancer

Start: 2022-08-05End: 2027-06-30Updated: 2026-08-31

Related Papers

Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR -altered non-small-cell lung cancer

Future Oncology2026-08-24

Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory <i>EGFR</i>-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.

Journal of Clinical Oncology2024-06-0515 citations

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Nature Medicine2023-09-1495 citations